Tysabri (Natalizumab) and PML – Update

Medical News: FDA Adds PML Risk to MS Drug Label – in Product Alert, Prescriptions from MedPage Today

A warning of a risk of progressive multifocal leukoencephalopathy has been added to the label for the multiple sclerosis drug natalizumab (Tysabri), the FDA announced. The labeling change was prompted by continuing reports of PML in MS patients. The current number of confirmed cases stands at 31 — 10 in the U.S. — up from 13 as recently as last September.

Scary Charts of the Day – 2/2/10

The Next Leg Of The Housing Crisis In Five Simple Charts | zero hedge

You may wonder why I continue to post charts on the economy in a life underwriting blog and website.  Here’s why.

People under financial strain will sometimes resort to extraordinary measures.  In this economy, pay extra attention to your financial underwriting.

Financial underwriting matters more now than it ever has in a very long time.